In September 2026, the FDA convened to confront one of modern medicine's more philosophically charged questions: how quickly should a society open the door to treatments that challenge its own regulatory assumptions? Psychedelic therapies — long exiled by stigma — have earned serious clinical credibility, and the agency now faces the task of building a framework that honors both the urgency of suffering and the discipline of safety. The outcome of this deliberation may define not just the future of psilocybin and MDMA treatments, but the very logic by which emerging psychiatric medicine finds